Abstract
ADV7103 is a galenic formulation of prolonged-release potassium citrate and potassium bicarbonate granules with a simplified twice-daily dosing regimen that has demonstrated better plasma bicarbonate management in patients with distal renal tubular acidosis (dRTA) than standard of care treatments requiring multiple daily intakes, while maintaining normal plasma potassium levels. If not adequately managed, clinical consequences of dRTA include failure to thrive, progressive kidney function decline and bone complications.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
